Repression of interferon regulatory factor-4 (IRF4) hyperactivation restricts murine lupus
Shijun He, Huihua Ding, Li Chen, Yiwei Shen, Yuting Liu, Fenghua Zhu, Xiaoqian Yang, Nan Shen, Zemin Lin, Jianping Zuo
Abstract
Hyperactivation of the type I interferon (IFN) signature has been observed in several systemic autoimmune conditions, and the type I IFN receptor antagonist Saphnelo (anifrolumab-fnia) has been approved in 2021 by the Food and Drug Administration (FDA) in the US. The launch of Saphnelo marked the only new treatment approved for systemic lupus erythematosus (SLE) in more than 10 years.
Topics & Concepts
IRF4Psychological repressionInterferon regulatory factorsSystemic lupus erythematosusCancer researchInterferonIRF1ImmunologyHyperactivationBiologyMolecular biologyVirologyMedicineTranscription factorGeneticsInternal medicineGeneGene expressionDiseaseSystemic Lupus Erythematosus ResearchCytokine Signaling Pathways and Interactionsinterferon and immune responses